California Institute of Technology

Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Aegerion Pharmaceuticals, Inc.

Amryt Pharmaceuticals Inc.

Zijian Guo

Soumitra S Ghosh

Mary Erickson

David C Litzinger

Jonathan David Roth

William G Dunphy

Abhinandini Sharma

Lala Mamedova

Caroline Ekblad

Manoj P Samant

Odile Esther Levy

Christopher Joseph Soares

Chengzao Sun

Swetha Neravetla

Esther Odile Levy

Akiko Kymagai

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

Engineered polypeptides having enhanced duration of action

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Engineered polypeptides having enhanced duration of action with reduced immunogenicity

The present invention provides compositions of ATR nucleic acids and proteins, as well as methods of using said compositions in screening assays. The invention further provides antibodies and transgenic animals based on the ATR compositions.

Cloning and functional assays of Xenopus ATR

The present invention provides polypeptides (Cds1) that are involved in regulating the progression of the cell cycle. The polypeptides are activated by double-stranded DNA and phosphorylated in response to the presence of double-stranded DNA. Also provided are polynucleotides encoding Cds1 polypeptidese and methods for modulating cell cycle progression in a cell.

Checkpoint-activating oligonucleotides

Growing community of inventors

San Diego, CA, United States of America

Zijian Guo